EP4512424A3 — Method and composition for treating ocular hypertension and glaucoma
Assigned to Santen Pharmaceutical Co Ltd · Expires 2025-03-05 · 1y expired
What this patent protects
The present invention relates to a preservative-free prostaglandin eye drops for glaucoma patients for single use, wherein said preservative-free prostaglandin eye drops are filled in a container consisting essentially of low density polyethylene with 0.2-0.5 mL of solution conta…
USPTO Abstract
The present invention relates to a preservative-free prostaglandin eye drops for glaucoma patients for single use, wherein said preservative-free prostaglandin eye drops are filled in a container consisting essentially of low density polyethylene with 0.2-0.5 mL of solution containing 0.0010-0.0025% tafluprost as an active ingredient, 0.05-0.1% polysorbate 80 and 0.01-0.1% disodium edetate.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.